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Parasitic infections induce a magnitude of host responses. At the opposite ends of the spectrum are those that ensure the
host’s needs to eliminate the invaders and to minimize damage to its own tissues. This review analyzes how parasites would
manipulate immunity by activating the immunosuppressive nuclear factor, peroxisome proliferator-activated receptors (PPARs)
with type 2 cytokines and free fatty acids from arachidonic acid metabolism. PPARs limit the action of type 1 immunity, in which
classicallyactivatedmacrophagesactthroughtheproductionofproinﬂammatorysignals,tosparetheparasites.Theyalsofavorthe
development of alternately activated macrophages which control inﬂammation so the host would not be destroyed. Possibly, the
nuclear factors hold a pivotal role in the establishment of chronic infection by delicately balancing the pro- and anti-inﬂammatory
signaling mechanisms and their ligands may be used as combination therapeutics to limit host pathology.
1.Introduction
Infection is the outcome of a contest between a pathogen
and its host. The host responds to an invasion by activation
of inﬂammation and launching of innate and speciﬁc
immunity. The goal is to eliminate the pathogen. On the
other hand, the pathogen seeks to proliferate and spread
to a new host when one is destroyed. The task of parasites
is particularly challenging because they need to strike a
balance between their own and the host’s defense so they can
continue to take advantage of the host to survive. It is well-
known that parasites are mostly immunosuppressive; the
mechanisms they use to penetrate immune defense may be
unique or shared by many species. Among the many means
of surviving host immunity, one that has recently emerged
is the activation of PPAR. This strategy promotes parasite
survival by increasing energy metabolism and suppressing
inﬂammation to allow invasion and avoid host destruction.
The goal of this article is to review our current knowledge on
h o wa c t i v a t i o no fP P A Rm a ya ﬀect the survival of parasites
and their hosts.
2. PeroxisomeProliferator-ActivatedReceptors
PPARs are ligand-activated transcription factors of the
nuclear hormone receptor superfamily that consists of over
48 transcription factors. There are three PPAR isoforms—
PPARα,P P A R β/δ,a n dP P A R γ also known as NR1C1,
NR1C2, and NR1C3, respectively, and they diﬀer in tissue
distribution and function [1, 2]. PPARα is expressed in a
variety of tissues involved in fatty acid oxidation, mainly
the hepatocytes, cardiac myocytes, and proximal tubular
epithelial cells of the kidney. It was so named because it
was found to induce proliferation of peroxisomes in rodent
livers (but not humans) when activated. Whereas PPARα has
limited tissue expression, PPARβ/δ is expressed ubiquitously
and plays an important role in energy homeostasis. PPARγ
is a master regulator of adipocyte diﬀerentiation and is an
important determinant of insulin sensitivity. Two subtypes
are known in mice and four in humans [3, 4]. They are
most highly expressed in adipose tissue, the colonic mucosal
epithelium, and cells of the immune system.2 Journal of Biomedicine and Biotechnology
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Figure 1: Domain structure of PPARs. PPARs contain the following functional regions: a N-terminal domain with AF-1 domain (ligand-
independent activation domain), a DNA binding domain (DBD) with two zinc ﬁngers, a hinge region, and a C-terminal ligand binding
domain (LBD) and AF-2 domain (ligand-dependent activation domain).
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Figure 2: General Schematics of PPAR function. General mechanisms of (a) genomic expression and (b) transrepression of gene expression
by PPAR/RXR heterodimers. In (a), upon ligand binding PPAR associates with RXR and coactivator to turn on target genes via the
PPAR response element (PPRE). In (b), blocking the dissociation of corepressor from transcription factor at the gene locus, association
of transcription factor to PPAR/RXR by tethering, and association of coactivator with PPAR/RXR by squelching, inhibit the transcription
of diﬀerent genes. R = corepressors, ﬁlled circle = ligand, A = coactivators, TF = transcription factor. Su indicates modulation by small
regulatory protein (sumoylation).
Structurally, PPARs have a DNA-binding domain, a
ligand-binding domain, two activation function sites, as well
as sites for phosphorylation and dimerization (Figure 1)
[2, 5, 6]. Activation is primarily ligand dependent and
heterodimerization with the retinoid X receptor (RXR) is
necessary. Figure 2 shows a simpliﬁed scheme of PPAR func-
tioningenomicexpressionandtransrepression.Endogenous
ligands for the PPARs include free fatty acids. Eicosanoids
and 9-cis-retinoic acid bind to the PPAR-RXR complex to
causeconformationalchangesthatdissociatethecorepressor,
setting the complex free to interact genomically with the
PPAR response element (PPRE), AGGTCANAGGTCA (two
AGGTCAsseparatedbyonenucleotide),locatedatthe5  end
of target genes (Figure 2(a)).
In contrast to genomic binding, PPARs also interact
with other transcription factors through nongenomic trans-
repression. In this process, they inhibit transcription by
preventing dissociation of corepressors or sequestering the
co-activators necessary for the binding of the transcription
factor to DNA [7, 8]. Both PPARα and γ suppress inﬂam-
mation and immunity by inhibiting the activation of major
transcriptionfactorsthatcontroltheexpressionofcytokines.Journal of Biomedicine and Biotechnology 3
For example, PPARα can tether on to the nuclear factor-
kappa B (NFκB) and prevent its transcription of interleukin-
6 (IL-6); sumoylated PPARγ can bind nuclear receptor core-
pressor (NCoR)-histone deacetylase 3 (HDAC3) complex to
prevent it from dissociating from NFκB and thus preventing
thegeneexpressionofinduciblenitricoxidesynthase(iNOS)
(Figure 2(b))[ 9].
3. ImmuneDefense againstParasiticInfections
Many parasitic infections are controlled by cell-mediated
immunity. For host protection, controlling parasite growth
relies on a type 1 response with activation of the classically
activatedmacrophages(caMac,alsoknownasM1),Thelper-
1 (Th1), Th17, the production of proinﬂammatory media-
tors, such as IL-1β, IL-6, tumor necrosis factor α (TNFα),
IL-12, IL-23, IL-27, interferon γ (IFNγ), and generation of
nitric oxide. On the contrary, a type 2 response with Th2
cells that produce IL-4 and IL-13 would render the host
susceptible to infection. These cytokines activate PPARγ,
which suppresses production of proinﬂammatory cytokines,
are critical for the formation, activation, and maintenance
of a subpopulation of macrophages, alternatively activated
macrophages(aaMac,alsoreferredtoasM2)[10].AaMacare
found during parasitic infections and have been associated
with downregulation of type 1 immunity as well as the
survival of both protozoa and helminthes. This emerging
subject of investigation has been reviewed recently by Reyes
andTerrazas[11]andotherinvestigators[12,13].AaMacnot
only inhibit T cell proliferation, but also promote resolution
of inﬂammation and ﬁbrogenesis. They actively express a
set of genes enabling them to regulate anti-inﬂammatory
processes, induce tolerance and wound healing. These anti-
inﬂammatory regulatory mechanisms can act as a counter-
balance to limit disease severity and protect the host from
detrimental eﬀects of an excessive type 1 response.
4. PPARs Regulate ImmuneResponses
Given the role of PPARs in metabolism and adipocyte dif-
ferentiation, it is intriguing that lipid-activated transcription
factors such as PPARs have a role in human immune cell
regulation. Initial documentation of PPAR activation in the
immune system occurred in 1994 [14]. PPARs were origi-
nally described in monocytes and macrophages, neutrophils
and peripheral blood lymphocytes. They have since been
reportedtoexistinotherimmunecelltypesofhematopoietic
origin, including T lymphocytes, B lymphocytes, NK cells,
dendritic cells, eosinophils, and mast cells. The extensive
expression by many immune cell types suggests that this
nuclear receptor may play a very important role in the
regulation of immune responses [15–20].
Immune regulation through the activation of PPARs
can occur in response to various long chain unsaturated
fatty acids generated from the cyclooxygenase and lipoxy-
genase pathways [21]. The eicosanoid 15-deoxy-Delta12,14-
prostaglandin J2 (15d-PGJ2) produced during arachidonic
acid metabolism can activate PPARγ during inﬂammatory
responses. Additional known ligands for include leukotriene
B4, 8(S)-hydroxyecosatetraenoic acid (HETE), 15-HETE,
and 13-hydroxyoctadecadienoic acid (13-HODE). Both 15-
HETE and 13-HODE can be produced via the action
of 12/15 lipoxygenase. Cytokines through induction of
cyclooxygenase and lipoxygenase can regulate the expression
and activity of PPARγ; for example, IL-4 induces 12/15
lipoxygenase and production of 15-HETE and 13-HODE
whereas IL-13 enhances COX-2 expression and production
of PGE2 and 15d-PGJ2 [22–24].
PPAR activation is generally known to result in an
anti-inﬂammatory environment and may exert an eﬀect
on the immune response by an array of mechanisms [9,
25–28]. PPARα and γ exert anti-inﬂammatory activities
through their ability to antagonize other signaling pathways,
in part through the interaction with other transcription
factors, including NFκB, activator protein-1 (AP-1), and
signal transducers and activators of transcription (STATs).
PPARγ agonists inhibit cell-mediated immunity by sup-
pressing the production of inﬂammatory cytokines like
TNFα,I L - 6 ,I L - 1 β,a n dI L - 1 2[ 29]. They exhibit sup-
pression on eﬀector mechanisms of classically activated
macrophage—inhibiting induction of inducible nitric oxide
synthase (iNOS), matrix metalloproteinase-9 (MMP-9), and
scavenger receptor A [17]. In mouse thioglycolate-elicited
macrophages, PPARγ inhibits recruitment of macrophages
tothesitesofinﬂammationbyrepressingthetranscriptionof
monocytechemoattractantprotein-1(MCP-1)anditsrecep-
tor CC chemokine receptor 2 (CCR2) in macrophages [29].
With respect to T cells, PPARs aﬀect activation and
eﬀector mechanisms via binding and blocking the action
of nuclear factor of activated T cells (NFAT), a transcrip-
tion factor. Speciﬁcally, 13-HODE, an endogenous PPARγ
agonist, prevents NFAT association with the IL-2 promoter,
thus inhibiting clonal T cell proliferation [20]. PPARα has
also been shown to repress production of IFNγ and IL-17
by CD4+ T cells, and PPARγ ligands modulate dendritic cell
function to elicit the development of anergic CD4+ T cells.
Whereas PPARs downregulate type 1 immunity they
upregulate type 2 responses. A study by Dasgupta et al.
[30] showed that gemﬁbrozil, a PPARα agonist, increases
the activity of the transcription factor GATA-3 and inhibits
expression of the transcription factor T-box expressed in T
cells (T-bet) to cause increase in IL-4 production by Th2
cells.Inapositivefeedbackmanner,IL-4hasalsobeenshown
to simultaneously increase the expression of PPARγ and
12,15-lipooxygenase, the enzyme involved in the generation
of 13-HODE [22].
5.ActivationofPPARsinParasiticInfections
By rendering the host less capable of an inﬂammatory burst,
PPAR activation might favor the establishment of a chronic
parasitic infection, making symbiotic survival between host
and parasite more likely. Plasmodium falciparum and Schis-
tosoma mansoni infection produce hemozoin, which induces
the release of endogenous ligands lipoxin A4 (LXA4), 5,15-
diHETE, and 15-HETE, that can activate PPAR. Production
of IL-4 and IL-13 in Leishmania and Toxoplasma infections4 Journal of Biomedicine and Biotechnology
also favors the activation of aaMac whose development is
dependent on PPARγ.
5.1. Hemozoin. The Plasmodium protozoa are parasites that
cause malaria. During disease pathogenesis, rapid growth of
merozoites within red blood cells leads to host cell rupture
and as the disease progresses, reinvasion of released parasites
heigthens parasitemia. As red blood cells and hemoglobin
are destroyed, the malaria parasite produces hemozoin, a
molecule formed via heme-catalyzed lipoperoxidation as a
detoxiﬁcation product and released together with other cell
debris [31].
Plasmodium hemozoin reacts with membrane phospho-
lipidstogeneratehydroxy-polyunsaturatedfattyacids,which
are ligands of PPARγ. The fact that hemozoin activity
is dependent on PPARγ has been demonstrated with the
PPAR agonist ciglitizone, the antagonist GW9662, and the
PPARγ ligand 15-HETE. Hemozoin has long been known
to be a potent modiﬁer of myeloid cells. It modulates
phagocytosis, activation by inﬂammatory cytokines, and
generation of the oxidative burst in monocytes. It also
inhibits granulocyte-macrophage colony stimulating factor
(GM-CSF) and IL-4-mediated diﬀerentiation of human
monocytes into immature dendritic cells. Furthermore,
hemozoin-loaded immature dendritic cells are also unable
to diﬀerentiate into mature dendritic cells. In these cells,
the PPARγ mRNA level increases, whereas the expression of
MHC class II, costimulatory molecules CD83, CD80, CD54,
CD40,CD1a,andCD83-speciﬁcmRNAarelowered[32,33].
In addition to Plasmodium, the metazoan parasite Schis-
tosoma mansoni, commonly known as blood ﬂuke, also
produces hemozoin. The adults of this snail-transmitted
parasite feed on red blood cells in humans during part
of its life cycle and biomineralizes dimeric heme into an
inert crystalline pigment that is structurally identical to
Plasmodium falciparum hemozoin. The lipid coat of native
schistosome hemozoin is a complex mixture of both neutral
lipids and polyunsaturated fatty acids. It can generate, by
nonenzymatic catalysis, large amounts of lipoperoxidation
products, such as monohydroxy derivatives of arachidonic
(HETE) and linoleic (HODE) acid and 4-hydroxynonenal
(HNE), which are natural ligands of PPAR. Murine RAW
264.7 macrophage-like cells that have phagocytized schisto-
somal hemozoin are also decreased in lipopolysaccharide-
stimulated nitric oxide production [34–36].
Interestingly, the kissing bug Rhodnius prolixus,w h i c h
is the vector for Trypanosoma cruzi, the etiological agent of
Chagas’ disease, also crystallizes heme into a dark brown
pigment. Since this insect feeds on blood meal, a link may
be extrapolated between blood-feeding and hemozoin for-
mation. Production of this PPAR activating molecule can be
astrategycommonlyacquiredbybloodfeedingparasitesand
blood taking vectors to suppress host immune response [37].
5.2. Polyunsaturated Fatty Acids (PUFA). The protozoan
Toxoplasma gondii infects feline epithelium and grows intra-
cellularly in diﬀerent mammalian nucleated cells, but it does
not feed on or destroy red blood cells and does not produce
hemozoin. However, it induces the production of natural
ligandsforPPARfromplatelets.Infectioninducesplateletsto
releaseLXA4,5,15-diHETE,and15-HETEatveryhighlevels,
two orders of magnitude greater than those used to resolve
inﬂammation [38]. Toxoplasmosis is a chronic disease that
is contained by immunity. The disease is only manifested in
severely immunocompromised individuals and detrimental
to fetus in early gestation. Henderson Jr. and Chi [39]h a v e
reported that other PPAR activating lipids, for example,
13-HODE at 10 nanomole concentration has cytotoxicity
against the parasite (however, 12-HETE at 1μMd o e sn o t ) .
Currently, the role of PPARγ in toxoplasmosis remains to
be elucidated. However, it is possible for it to have a role
in maintaining a balance that supports host and parasite in
dormant, chronic infections.
5.3. Interleukin-4. The pivotal role of PPARγ on IL-4 and
aaMac-mediated susceptibility has been demonstrated in
Leishmania pathogenesis. Leishmaniasis is transmitted by
the sandﬂy vector carrying parasitic protozoa of the genus
Leishmania. Clinically the disease can be manifested in three
major types, cutaneous, mucocutaneous, and visceral, each
caused by diﬀerent species of the protozoan genus. In the
murine model of the cutaneous infection, BALB/c mice, the
Leishmaniamajor susceptiblestrains,haveaThelper2(Th2)
response whereas the C57BL/6 mice, resistant strains, have a
T helper-1 (Th1) response [40]. AaMacs are found in all Th2
cytokine environments. Interestingly, BALB/c mice are more
supportive of aaMac maturation than C57BL/6 mice, which
are resistant to leishmaniasis [41].
PPARγ expression is strongly associated with maturation
of aaMac. Our laboratory investigated visceral leishmaniasis
and found that Leishmania donovani induces PPARγ expres-
sion in residential macrophages, liver and spleen of BALB/c
mice. In addition, oral administration of the PPARγ agonist,
curcumin further increases PPARα and PPARγ expression,
and the increase is associated with a heavier parasite burden
(Figure 3)[ 42].
Consistent with our ﬁndings, cutaneous Leishmania
infection is less severe in mice whose PPARγ gene has been
knocked out in their macrophages (Mac-PPAR KO). Mac-
PPAR KO mice had signiﬁcantly less footpad swelling 5–
7 weeks after injection of L. major promastigotes. Lesions
in Mac-PPAR KO started to stabilize after 7 weeks, but the
footpads of wild type mice continued to enlarge and rapidly
underwent necrosis. The loss of PPARγ is associated with
loss of aaMac, as cells that express their phenotypic marker,
arginase I, are decreased. The production of nitric oxide and
IL-6, correspondingly, is increased as well [41].
PPARγ and PPARδ regulate expression of the arginase I
gene, a key marker, in aaMac. The PPARγ agonist GW7845
and PPARδ agonist GW0742 activate arginase in murine
macrophages, and this activation only occurs in wild type
macrophages that have PPARγ or PPARδ,b u tn o ti nc e l l s
where either of their genes has been knocked out [43].
Arginase decreases the amount of arginine, the substrate
for NOS to produce nitric oxide. Since intracellular killing
of amastigotes requires nitric oxide, both cutaneous and
visceral infections are unrestrained in iNOS knockout mice
[44–46].Journal of Biomedicine and Biotechnology 5
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Figure 3: PPAR-mediating suppression of parasiticidal response in leishmaniasis. The sandﬂy vector carries leishmanial promastigotes to the
mammalian host. The parasites then transform into amastigotes within phagolysosomes of host macrophages. Type 1 immunity, with T
helper 1 (Th1) releasing interferon γ (IFNγ), leads to classically activated macrophages (caMac). CaMac produce nitric oxide from inducible
nitric oxide synthase (iNOS), interleukin-1 (IL-1), tumor necrosis factor (TNF), and reactive oxygen and nitrogen intermediates (ROI, RNI)
that act to eliminate the amastigotes. Type 2 immunity, with Th2 releasing IL-4, leads to activation of peroxisome proliferator-activated
receptor (PPAR) and alternatively activated macrophages (aaMac). AaMac produce arginase, IL-10, transforming growth factor β (TGFβ),
and PPAR that allow amastigote propagation. PPAR agonists (GW7845 and GW0742) and some phytochemicals (curcumin) can activate
PPAR and promote aaMac maturation. Activation of PPAR allows parasite survival as a chronic parasitic infection.
5.4. Interleukin-13. IL-13, another Th2 cytokine that shares
a common receptor chain with IL-4, exerts similar eﬀects
on macrophages [13]. Functionally, it inhibits the activation
of caMac and the production of Th1 cytokines and reactive
nitrogen species. The eﬀect of IL-13 is also mediated via the
PPARγ pathway. In Toxoplasma-infected macrophages, IL-
13 activates PPAR by inducing the production of 15d-PGJ2.
Exogenous addition of PPARγ agonists, rosiglitazone or 15d-
PGJ2, mimics IL-13 in that it induces CD36, the scavenger
receptor whose transcription is turned on by PPARγ [47].
This eﬀect can be further extended to aaMac; IL-13−/− mice
are incapable of generating cells that express the aaMac
phenotype(chitinase-likelectinYM1orCD20)[48].CD36is
classiﬁed as a class 2 scavenger receptor [49–51]. It is present
on the cell surface of many cell types, including mono-
cytes and macrophages. The molecule recognizes oxidized
low density lipoprotein (LDL), oxidized phospholipids and
lipoproteins, apoptotic cells, and microbial pathogens. With
respect to parasites, Plasmodium falciparum erythrocyte
membrane protein 1 (PfEMP-1), commonly found in the
schizont stage, ring stage and early gametocytes (stage I
and IIA), serves as a ligand for CD36. Binding to CD36
is necessary for phagocytosis of P. falciparum-parasitized
erythrocytes by human and rodent monocytes/macrophages
[52–57]. The function of PPARγ in CD36-mediated phago-
cytosis is illustrated by the fact that IL-13-induced clearance
of the parasitized erythrocytes is blocked by anti-CD36 and
GW9662, a PPARγ antagonist [47]. The activity, however,
is enhanced by the agonists 15d-PGJ2 and ciglitazone [52].
T h er o l eo fP P A R γ in CD36-medited phagocytosis is also
conﬁrmed by the observations that mice treated with rosigli-
tazone have reduced parasitemia of Plasmodium chabaudi,
whereasthisreductionisnotseeninCD36knockoutanimals
[57]. CD36-mediated phagocytosis will facilitate removal
of neutrophils and dead tissues to resolve inﬂammation as
well as clearing of the parasite [52]. Consistent with this6 Journal of Biomedicine and Biotechnology
Table 1: Eﬀect of PPAR modulation on the outcome of parasitic infections.
Parasite Animal model Treatment PPAR status Outcome Reference
Increase in parasite
load
Leishmania major Murine cutaneous leishmaniasis Gene knockout PPARγ−/−
macrophages
Decreased footpad
swelling
[41]
Leishmania donovani Murine visceral leishmaniasis Curcumin PPARγ ↑
PPARα ↑
Increased parasite
load
[42]
Decrease in host
tissue damage
Schistosoma
japonicum
Murine hepatic ﬁbrosis Rosiglitazone
(Praziquantel) PPARγ ↑ Decreased ﬁbrosis [60]
Plasmodium berghei Murine cerebral malaria Rosiglitazone Not stated Increased survival [57]
Plasmodium chabaudi Murine malaria Rosiglitazone Not stated Decreased
parasitemia
[57]
conceptthatPPARandaaMacresolveinﬂammation,Herbert
et al. [58] reported that in the absence of IL-4/IL-13-induced
aaMac, mice with their macrophage-speciﬁc IL-4 receptor
knockout (LysMCreIL-4R
−/ﬂox ) die of schistosomiasis. The
mutant mice have increased Th1 cytokines and nitric oxide,
hepatic and intestinal histopathology due to lack of aaMac
to protect against tissue injury. Correspondingly, BALB/c
mice with their T helper-1 responses and immunopathology
down-modulated by aaMac survive Schisotsoma mansoni
infection better [59].
Henceforth, in sum, studies have revealed that PPARγ
suppresses immune reaction to parasitic infection; however,
it also plays a role, perhaps through a CD36-dependent
manner, in reducing parasitemia as well as resolving inﬂam-
mation.
6. Effect of Pharmacological PPAR
Ligandson ParasiticInfections
The anti-inﬂammatory actions of PPARγ have received great
attention because of the availability of synthetic PPARγ
activator molecules and their clinical use. The FDA has
approvedseveralsyntheticPPARligandsastherapeuticdrugs
[59, 61]. For example, cloﬁbrate, an agonist of PPARα,
and its related compounds are used for the treatment
of dyslipidemia. Rosiglitazone (drug name Avandia) and
pioglitazone (drug name Actos), agonists of PPARγ,a r eu s e d
in the management of type 2 diabetes. The drugs improve
insulin sensitivity by controlling metabolic and endocrine
functions of the adipose tissue. PPARs are attractive drug
targets for energy homeostasis and control of lipid and
glucose metabolism, as well as possible body weight control.
Dual agonists of PPARs have been sought, even though
troglitazone and muraglitazar (dual agonist for PPARα/γ),
originallyapprovedbyFDAwerelaterwithdrawnduetoliver
toxicity and increased cardiovascular risks, respectively [62,
63]. PPARγ remains a promising target; safer therapeutics
may still become a reality in the future.
Potentially, PPAR ligands may be used in parasitic
diseases. To date, in experimental models PPAR ligands have
been shown to alleviate host tissue destruction by immune
response, as seen in malaria and schistosomiasis. Recently,
Lena Serghides and colleagues have shown that rosiglitazone,
the PPARγ agonist, is useful in alleviating cerebral malaria
in a murine model [57]. Among the variety of symptoms
of malaria, cerebral malaria is the deadliest complication
that aﬀects an estimated total of 785,000 children in Africa
each year. Acutely manifested, the Plasmodium falciparum
parasites induce fever, changes in mental status, and coma.
The sequestration of parasitized red blood cells (PRBCs) and
non-PRBCs in the cerebral capillaries and venules reduces
microvascular blood ﬂow and induces hypoxia in the brain.
Furthermore, the parasites stimulate the host macrophages
to release TNFα, IL-1, and uncontrolled production of nitric
oxide, which diﬀuses through the blood-brain barrier and
acts on synaptic function, leading to a state of reduced
consciousness. Cotreatment of rosiglitazone (50mg/kg of
chow) with Plasmodium berghei-parasitized erythrocytes to
susceptible mice leads to animal survival.
Similarly, PPAR ligands may be useful in human schisto-
somiasis, a chronic infection that can cause liver ﬁbrosis. In
a murine experimental model of hepatic ﬁbrosis induced by
Schistosoma japonicum, Chen and colleagues [60]r e p o r t e d
that coadministration of rosiglitazone (4mg/kg), daily for 6
weeks (at 4 weeks after infection) with the antischistosomal
drug praziquantel (500mg/kg) alleviates the symptoms of
liver ﬁbrosis. This was demonstrated by a decrease of ﬁbrosis
markers, type I and III collagen, and smooth muscle α
actin. The decrease in ﬁbrosis is accompanied by reduced
bindingactivityofthetranscriptionfactorNFκBandlowered
levels of TNFα and IL-6 in the serum. Like cerebral malaria
data, these ﬁndings also suggest that the PPARγ ligand
rosiglitazone may be clinically useful for treatment of liver
ﬁbrosis due to schistosomal infection.
7. Conclusion andFutureProspects
In conclusion, to date, the role of PPARγ in parasitic diseases
remains largely unexplored. Recent evidence suggests that
PPARγ activationmayincreasereplicationofparasitesaswellJournal of Biomedicine and Biotechnology 7
as maintain survival of the host (Table 1). Perhaps it is a
measure by which a chronic infection can be established. In
a strong cell-mediated immunity, a typical type 1 immune
response induces the production of TNFα,I F N γ, and nitric
oxide which eliminates parasites. However, the host will
severely suﬀer from tissue destruction during this process,
a sc a nb es e e ni nc e r e b r a lm a l a r i a ,w h e nt h ec h i l d r e nm a y
be comatose, and in late stages of visceral leishmaniasis,
when the patients may be cachexic and their liver and
spleen are enlarged. A type 2 response with IL-4 and IL-
13 which induces immunosuppressive PPARs would allow
the parasites to infect, but spare the host of devastating
tissue destruction. In leishmaniasis, for example, activation
of PPARγ by curcumin suppresses IFNγ and nitric oxide
production and increases parasite burden. It may be of
interest that curcumin is prevalently used for medicine,
cosmetics, and cooking in India, where visceral leishmaniasis
is endemic. Perhaps, through PPARγ the host can resolve
inﬂammation and repair tissues to strive for a balance
betweenthehostandtheparasitethatfavorsmutualsurvival.
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